Key result
Monoclonal antibodies 7B3 and 14B1 protected 100% of K18-hACE2 mice from lethal SARS-CoV-2 WT and Delta variant challenges, and 7B3 provided therapeutic protection against Omicron BA.1 and BA.2.
Why the study?
Do monoclonal antibodies derived from early COVID-19 convalescents prevent lethal SARS-CoV-2 infection in K18-hACE2 KI mice?
Do monoclonal antibodies derived from early COVID-19 convalescents prevent lethal SARS-CoV-2 infection in K18-hACE2 KI mice?
Monoclonal antibodies 7B3 and 14B1 derived from early COVID-19 convalescents broadly neutralize SARS-CoV-2 variants and protect mice from lethal infection.
Answers are grounded in this paper and cite their sources.
Broadens candidate pool for variant-resistant mAbs; leaves open clinical translation and in vivo efficacy.
Coronavirus disease 2019 (COVID-19) was first reported three years ago, when a group of individuals were infected with the original SARS-CoV-2 strain, based on which vaccines were developed. Here, we develop six human monoclonal antibodies (mAbs) from two elite convalescents in Wuhan and show that these mAbs recognize diverse epitopes on the receptor binding domain (RBD) and can inhibit the infection of SARS-CoV-2 original strain and variants of concern (VOCs) to varying degrees, including Omicron strains XBB and XBB.1.5. Of these mAbs, the two most broadly and potently neutralizing mAbs (7B3 and 14B1) exhibit prophylactic activity against SARS-CoV-2 WT infection and therapeutic effects against SARS-CoV-2 Delta variant challenge in K18-hACE2 KI mice. Furthermore, post-exposure treatment with 7B3 protects mice from lethal Omicron variants infection. Cryo-EM analysis of the spike trimer complexed with 14B1 or 7B3 reveals that these two mAbs bind partially overlapped epitopes onto the RBD of the spike, and sterically disrupt the binding of human angiotensin-converting enzyme 2 (hACE2) to RBD. Our results suggest that mAbs with broadly neutralizing activity against different SARS-CoV-2 variants are present in COVID-19 convalescents infected by the ancestral SARS-CoV-2 strain, indicating that people can benefit from former infections or vaccines despite the extensive immune escape of SARS-CoV-2.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2023) studied SARS-CoV-2 infection. Monoclonal antibodies 7B3 and 14B1 vs. Isotype control was evaluated on Survival rate at 8 days post-infection. Monoclonal antibodies 7B3 and 14B1 protected 100% of K18-hACE2 mice from lethal SARS-CoV-2 WT and Delta variant challenges, and 7B3 provided therapeutic protection against Omicron BA.1 and BA.2.
Synapse has enriched 10 related papers. Consider them for comparative context: